Lonza has completed the expansion of its mid-scale microbial manufacturing facility in Visp, Switzerland.
The manufacturing partner's production site was recently granted a GMP license from Swissmedic, meaning Lonza is considered cGMP-compliant.
The newly extended facility houses two 4,000L fermenters, with a large proportion of the site's processes being automated for enhanced efficiency and quality.
The microbial manufacturing facility was strategically expanded to enhance Lonza's flexibility in offering scale-up approaches for customers.
The company can now more comprehensively offer a phase-appropriate supply of microbes to fit the needs of drug developers globally.
Michael De Marco, Vice President, Head of Microbial, Lonza, commented: “Microbial manufacturing is a well-established and a favoured option for producing complex proteins. Recent growth in the heterogeneity of the biotech pipeline, alongside the growth of smaller and more complex next-generation molecules, has increased demand for microbial manufacturing capacity."
"This expansion adds to our suite of scales and further strengthens our offering to flexibly adapt to all demand and life cycle scenarios of our customer’s medicines.”
